Skin Biopsy Market Overview
Skin Biopsy Market Size was valued at USD 1.1 Billion in 2023. The Global Skin Biopsy industry is projected to grow from USD 1.2 Billion in 2024 to USD 1.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.09% during the forecast period (2024 - 2032).
Skin biopsy is a procedure involving the removal of skin for examination and providing information about any disease or clinical conditions. It is performed to determine the presence of any cancerous cells or any type of skin diseases. Skin cancer, actinic keratosis, dermatitis, psoriasis, and skin infection are various diseases that can be diagnosed through skin biopsy. During the procedure, the sample taken from the affected or diseased part of the skin is placed in formaldehyde solution, the tissue is processed and then examined under the microscope.
Rising of skin cancer and number of skin disease such as psoriasis, viral skin infection, and dermatitis, and growing demand for minimally invasive medical procedures are major factors contributing to the market growth. Furthermore, rising expenditure on the medical devices and instruments boost the market growth. However, high cost of treatment for skin diseases restrains the market.
Skin Biopsy Market Segmentation
The global skin biopsy market is segmented on the basis of type, devices, indication, and end user.
On the basis of type, skin biopsy market is segmented into shave biopsy, punch biopsy, excisional biopsy and incisional biopsy.
On the basis of devices, the skin biopsy market is segmented into needle based biopsy guns, biopsy curettes and punches, guidance systems, biopsy forceps, biopsy needles and others.
On the basis of indication, the skin biopsy market is segmented into actinic keratosis, dermatitis, psoriasis, skin infection, cancer, and others.
Skin infection is further segmented into viral infections, deep fungal infections, basal cell carcinoma, squamous cell carcinoma, and melanoma.
On the basis of end user, the market is segmented into hospitals, dermatology clinics, and others.
Regional Analysis of the Global Skin Biopsy Market
America secures a leading position in the market for skin biopsy owing to the rising prevalence of skin diseases and cancer in the U.S. and presence of key market players. According to the American Academy of Dermatology (AAD), skin diseases affects one in every fourth American. The prevalence of skin diseases is also found to be increasing in Canada.
Europe is the second largest market for skin biopsy. Increasing prevalence of skin diseases such as fungal infections, and dermatitis, and increasing demand for technological advanced diagnostic services further drive the market growth.
The skin biopsy market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising geriatric population, rising prevalence of skin cancer, and increasing number of biopsies performed in the hospitals.
The Middle East & Africa also show a steady rise in the skin biopsy market owing to increasing prevalence of diabetes and other chronic diseases
Key Players in the Global Skin Biopsy Market
- Boston Scientific Corporation (U.S.)
- COOK Medical (U.S.)
- BD (U.S.)
- DTR Medical Ltd (U.K)
- Devicor Medical Products, Inc.
- part of Leica Biosystems. (U.S.)
- Gallini Srl (Italy)
- Hologic, Inc. (U.S.)
- Cardinal Health (U.S.)
Intended Audience
- Biopsy Devices Manufacturers
- Biopsy Devices Suppliers
- Private Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Government Research Laboratories
Report Attribute/Metric |
Details |
Market Size |
 USD 1.8 Billion by 2032 |
CAGR |
 11.09% |
Base Year |
  2023 |
Forecast Period |
 2024-2032 |
Historical Data |
  2022 |
Forecast Units |
  Value (USD Million) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Type, Devices, Indication, And End User |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
 Key Vendors |
Boston Scientific Corporation (U.S.), COOK Medical (U.S.), BD (U.S.), DTR Medical Ltd (U.K), Devicor Medical Products, Inc. part of Leica Biosystems. (U.S.), Gallini Srl (Italy), Hologic, Inc. (U.S.), and Cardinal Health (U.S.) |
Key Market Opportunities |
Rising expenditure on the medical devices and instruments |
Key Market Drivers |
Rising of skin cancer and number of skin disease such as psoriasis, viral skin infection, and dermatitisGrowing demand for minimally invasive medical procedures |
Frequently Asked Questions (FAQ) :
Skin biopsy market is projected to grow at approximately 11.09% CAGR during the assessment period (2024-2032).
Increasing prevalence of skin diseases, rising awareness about skin cancer & its treatment, and growing demand for technologically advanced medical devices, are the major tailwinds pushing the growth of the global skin biopsy market.
High cost of treatment for skin diseases is a major growth impeder for the global skin biopsy market.
North America holds the largest share in the global skin biopsy market, followed by Europe and the Asia Pacific, respectively.
COOK Medical (U.S.), Boston Scientific Corporation (U.S.), BD (U.S.), Devicor Medical Products, Inc. part of Leica Biosystems. (U.S.), DTR Medical Ltd (U.K), Gallini Srl (Italy), Cardinal Health (U.S.), and Hologic, Inc. (U.S.), are some of the top players operating in the global skin biopsy market.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report